CMChongyang Ma

Chongyang Ma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chongyang Ma has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association between uric acid and non-alcoholic fatty liver disease in patients with hypertension

    by Yan Zhao, Zhenwei Wang, Yang Liu, Ting Yang, Zhuang Li, Ao Gao, Lei Cao, Chongyang Ma

    Serum uric acid (UA) is linked to non-alcoholic fatty liver disease (NAFLD), but its role in hypertensive populations remains unclear. This cross-sectional study investigated their association in 1,058 patients with hypertension. Multivariate logistic regression analysis confirmed that UA was independently correlated with NAFLD, whether as a continuous variable or a categorical variable. According to the fully adjusted model, the risk of NAFLD increased by 0.2%, 347.2% and 91.7% for each unit increase in UA, Log 10 UA and LnUA, respectively (P < 0.05). Multivariate stratified analysis revealed that UA increased the risk of NAFLD in specific subgroups, including males, individuals aged 70–79 years, non-smokers, those without diabetes, and obese individuals (P < 0.05). Receiver operating characteristic (ROC) analysis indicated that UA could not only predict the occurrence of NAFLD but also improve the predictive value of the baseline model for NAFLD (UA, AUC: 0.588; baseline model, AUC: 0.770; baseline model + UA, AUC: 0.772). In conclusion, UA is significantly associated with NAFLD in patients with hypertension and may serve as a predictive risk indicator.


  • Chaize mixture alleviates NAFLD by regulating Glipr2-related autophagy/NLRP3 signaling

    by Xiaohui Zhang, Juan Shi, Yutong Liu, Yun Lu, Jing Ji, Xueqian Wang, Jinying Liu, Fafeng Cheng, Qiuxia Zhang, Chongyang Ma


  • Liu-Jun-Zi decoction alleviates metabolic dysfunction-associated steatohepatitis by modulating myogenic irisin mediated skeletal muscle-liver crosstalk

    by Chunyu Wang, Kunjing Liu, Jing Ji, Wenyuan Ma, Haojia Zhang, Kai Wang, Yukun Lin, Chongyang Ma, Xueqian Wang, Fafeng Cheng


  • Open Access

    Amyotrophic lateral sclerosis and neurodegenerative diseases: A Mendelian randomization study

    by Chaofang Lei, Jiaxu Chen, Zhigang Chen, Yonghong Mm Xiao, Jianbei Chen, Chongyang Ma, Miaomiao Yang, Dahua Wu, Le Xie

    In this study, we used the Mendelian randomization (MR) method to systematically examine whether there is a bidirectional causal relationship between amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD), Parkinson’s disease (PD), frontotemporal dementia (FTD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB). We analyzed data from 6,44,924 participants using MR to evaluate causality. We employed inverse variance weighted and MR-Egger regression tests for MR analysis. Additionally, we performed sensitivity analyses using the MR-Egger test and Mendelian Randomization Pleiotropy RESidual Sum and Outlier. The inverse variance weighted analysis found no evidence of a risk effect between ALS and the neurodegenerative diseases AD, PD, FTD, MSA, and DLB. However, the MR-Egger analysis showed that both AD (odds ratio: 1.079, 95% confidence interval: 1.017–1.145, P = .029) and PD (odds ratio: 1.210, 95% confidence interval: 1.046–1.401, P = .020) have a risk effect on ALS, indicating that AD and PD increase the risk of ALS. Our MR analysis suggests that AD and PD may have a potential causal relationship with ALS. Conversely, ALS does not appear to have a causal relationship with the other neurodegenerative diseases examined (FTD, MSA, DLB).

  • Protective effects of berberine on MASLD: regulation of glucose and lipid metabolism through PI3K/Akt and STING pathways

    by Jing Ji, Ying Li, Tian Xu, Qi Shao, Zijin Sun, Simin Chen, Di Zhang, Qingguo Wang, Xueqian Wang, Chongyang Ma, et al.

    This study is aimed at exploring the therapeutic potential of berberine (BBR) in mitigating metabolic dysfunction-associated steatotic liver disease (MASLD) and at elucidating its mechanisms of action, with a focus on the modulation of glucose and lipid metabolism via the PI3K/Akt and STING signaling pathways. Male C57BL/6 J mice were fed a high-fat diet (HFD) to induce MASLD and subsequently treated with BBR or metformin. HepG2 cells were cultured in vitro, and palmitic acid (PA) was used to construct the cell model. Comprehensive analyses, including network pharmacology, transcriptome sequencing, and Western blotting, were conducted to identify critical pathways and molecular targets. Biochemical, histological, and molecular assays were performed to evaluate metabolic and inflammatory responses. BBR significantly attenuated HFD-induced hepatic steatosis, inflammation, and glucose intolerance. It effectively reduced lipid accumulation, enhanced insulin sensitivity, and modulated the expression of genes involved in lipid metabolism. Network pharmacology and transcriptome analysis highlighted the involvement of the PI3K/Akt and STING pathways. BBR activated PI3K/Akt signaling while suppressing the STING pathway, thereby reducing lipid accumulation in both in vivo and in vitro models. The inhibition of AKT negated the beneficial effects of BBR, underscoring the pivotal role of PI3K/Akt in regulating STING signaling. BBR ameliorates MASLD by activating the PI3K/Akt pathway and inhibiting the STING pathway, leading to improved glucose and lipid metabolism. These findings position BBR as a promising therapeutic candidate for the treatment of MASLD. Graphical Abstract


  • Open Access

    Linking Nonalcoholic Fatty Liver Disease and Brain Disease: Focusing on Bile Acid Signaling

    by Zi-Lin Ren, Chang-Xiang Li, Chong-Yang Ma, Dan Chen, Jia-Hui Chen, Wen-Xiu Xu, Cong-Ai Chen, Fa-Feng Cheng, Xue-Qian Wang

    A metabolic illness known as non-alcoholic fatty liver disease (NAFLD), affects more than one-quarter of the world’s population. Bile acids (BAs), as detergents involved in lipid digestion, show an abnormal metabolism in patients with NAFLD. However, BAs can affect other organs as well, such as the brain, where it has a neuroprotective effect. According to a series of studies, brain disorders may be extrahepatic manifestations of NAFLD, such as depression, changes to the cerebrovascular system, and worsening cognitive ability. Consequently, we propose that NAFLD affects the development of brain disease, through the bile acid signaling pathway. Through direct or indirect channels, BAs can send messages to the brain. Some BAs may operate directly on the central Farnesoid X receptor (FXR) and the G protein bile acid-activated receptor 1 (GPBAR1) by overcoming the blood–brain barrier (BBB). Furthermore, glucagon-like peptide-1 (GLP-1) and the fibroblast growth factor (FGF) 19 are released from the intestine FXR and GPBAR1 receptors, upon activation, both of which send signals to the brain. Inflammatory, systemic metabolic disorders in the liver and brain are regulated by the bile acid-activated receptors FXR and GPBAR1, which are potential therapeutic targets. From a bile acid viewpoint, we examine the bile acid signaling changes in NAFLD and brain disease. We also recommend the development of dual GPBAR1/FXR ligands to reduce side effects and manage NAFLD and brain disease efficiently.


  • Open Access

    Jieduan–Niwan Formula Ameliorates Oxidative Stress and Apoptosis in Acute-on-Chronic Liver Failure by Suppressing HMGB1/TLR-4/NF-κB Signaling Pathway: A Study In Vivo and In Vitro

    by Peng Fang, Bo Dou, Weixin Hou, Xiaoyi Wei, Jiajun Liang, Chongyang Ma, Qiuyun Zhang

    Jieduan-Niwan (JDNW) formula is a traditional Chinese medicine compound created by the famous Chinese medicine expert Professor Qian Ying, and has been used clinically for decades to treat acute-on-chronic liver failure (ACLF) and exhibits remarkable efficacy. However, the exact mechanism remains to be discovered. As an important hepatocyte damage-associated molecular patterns (DAMP) factor, high mobility group box 1 (HMGB1) is a potential therapeutic target as an accelerator of ACLF in the pathogenesis. Therefore, the present study investigated whether JDNW inhibits the overexpression and cytoplasmic translocation of HMGB1 in ACLF liver tissue and alleviates its mediated oxidative stress and apoptosis. In vivo, an immune-induced ACLF rat model was established, and then treated with JDNW for 5, 10, and 15 d. The results showed that a large number of cytoplasmic translocations of HMGB1 occurred in the ACLF group. And there was an increase in the expression of HMGB1 in the M-5d group. After the intervention of JDNW, the overexpression and translocation of HMGB1 were inhibited. In vitro, D-GaLN caused an increase in the expression and translocation of HMGB1 in L02 cells. Similar to the inhibitor of HMGB1, JDNW serum alleviated this kind of increase. Further tests showed that JDNW attenuated ACLF-related oxidative stress and apoptosis, and the inhibition was associated with the regulation of TLR-4/NF-κB signaling pathway. In conclusion, our present findings suggest that the therapeutic effect of JDNW on ACLF was associated with the inhibition of high expression and cytoplasmic translocation of HMGB1 during the acute injury phase, thus, attenuating oxidative stress injury and apoptosis induced by HMGB1/TLR-4/NF-κB pathway.


  • Open Access

    Agrimonia pilosa: A Phytochemical and Pharmacological Review

    by Tianyu Jin, Li Chi, Chongyang Ma

    Agrimonia pilosa Ledeb., which belongs to Agrimonia and Rosaceae, is used in traditional Chinese medicine. It exhibits excellent medicinal properties and has been used to treat various diseases, such as tumors, trichomoniasis, vaginitis, diarrhea, and dysentery. Phytochemical studies have revealed that Agrimonia has over 100 secondary metabolites that can be categorized into six classes, i.e., flavonoids, isocoumarins, triterpenes, phloroglucinol derivatives, tannins, and organic acids. This review summarizes recently published literature on the chemical structures of 90 bioactive compounds that have been identified in A. pilosa and examines their pharmacological properties, including their antitumor, anti-inflammatory, antioxidant, antibacterial, and antidiabetic properties, as well as the potential development of parasitic resistance to these chemicals. This review highlights existing knowledge gap and serves as a basis for developing novel preparations of A. pilosa with medicinal value.


  • Open Access

    Pharmacological Mechanisms of Tinglizi against Chronic Heart Failure Determined by Network Pharmacology and Molecular Docking

    by Liangtao Luo, Haowen Wang, Guowei Huang, Lu Zhang, Xiuwei Li, Chongyang Ma, Xing Wang

    Objective. Tinglizi has been extensively used to treat chronic heart failure (CHF) in modern times, but the material basis and pharmacological mechanisms are still unclear. To explore the material basis and corresponding potential targets and to elucidate the mechanism of Tinglizi, network pharmacology and molecular docking methods were utilized. Methods. The main chemical compounds and potential targets of Tinglizi were collected from the pharmacological database analysis platform (TCMSP). The corresponding genes of related action targets were queried through gene cards and UniProt database. The corresponding genes of CHF-related targets were searched through Disgenet database, and the intersection targets were obtained by drawing Venn map with the target genes related to pharmacodynamic components. Then, drug targets and disease targets were intersected and put into STRING database to establish a protein interaction network. The “active ingredient-CHF target” network was constructed with Cytoscape 3.8.2. Finally, Gene Ontology (GO) Enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment of intersection targets were analyzed using metascape. With the aid of SYBYL software, the key active ingredients and core targets were docked at molecular level, and the results were visualized by PyMOL software. Molecular docking was carried out to investigate interactions between active compounds and potential targets. Results. A total of 12 active components in Tinglizi were chosen from the TCMSP database, and 193 corresponding targets were predicted. Twenty-nine potential targets of Tinglizi on CHF were obtained, of which nine were the core targets of this study. Twenty GO items were obtained by GO function enrichment analysis ( ), and 10 signal pathways were screened by KEGG pathway enrichment analysis ( ), which is closely related to the treatment of CHF by Tinglizi. The constructed drug compound composition action target disease network shows that quercetin, kaempferol, and other active compounds play a key role in the whole network. The results of molecular docking showed that all the key active ingredients, such as quercetin and isorhamnetin, were able to successfully dock with ADRB2 and HMOX1 with a total score above 5.0, suggesting that these key components have a strong binding force with the targets. Conclusion. Through network pharmacology and molecular docking technology, we found that the main components of Tinglizi in the treatment of CHF are quercetin, kaempferol, β-sitosterol, isorhamnetin, and so on. The action targets are beta 2-adrenergic receptor (ADRB2), heme oxygenase 1 (HMOX1), and so on. The main pathways are advanced glycation end products/receptor for advanced glycation end products (AGE-RAGE) signaling pathway in diabetic complications, hypoxia-inducible factor (HIF-1) signaling pathway, estrogen signaling pathway, and so on. They play an integrated role in the treatment of CHF.